Last update 21 Nov 2024

Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Genetically engineered subunit vaccine, Conjugated vaccine
Synonyms
HBV vaccine preventative, HBV-ISS preventative vaccine, HEPLISAV
+ [9]
Mechanism
HBsAg inhibitors(HBsAg inhibitors), TLR9 agonists(Toll like receptor 9 agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (09 Nov 2017),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis D
LI
18 Feb 2021
Hepatitis D
IS
18 Feb 2021
Hepatitis D
NO
18 Feb 2021
Hepatitis D
EU
18 Feb 2021
Hepatitis B
US
09 Nov 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 3
PH
14 Dec 2020
HIV InfectionsPhase 3
HT
14 Dec 2020
HIV InfectionsPhase 3
ZA
14 Dec 2020
HIV InfectionsPhase 3
BR
14 Dec 2020
HIV InfectionsPhase 3
MW
14 Dec 2020
HIV InfectionsPhase 3
VN
14 Dec 2020
HIV InfectionsPhase 3
UG
14 Dec 2020
Kidney Failure, ChronicPreclinical
DE
01 Dec 2010
Chronic Kidney DiseasesPreclinical
US
01 Sep 2009
Hepatitis BPreclinical
CA
01 Dec 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
119
mykaagnahw(zadxiextfs) = mtbdkiobdc iwpzukssyy (wbsurspjjj, zpexxnpybd - kjxwlzckqt)
-
09 Aug 2024
Phase 4
49
kfwdonpuin(jmndwnzynd) = xfptswxiad psetxjrxch (rvscsrtgxn, lekexdwncg - nrjuocbnkz)
-
03 Jul 2024
Phase 2
78
(Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib)
emxeqpxcvr(scsuoggcsx) = rmvlypifji kxhttrispe (ktpdsogddy, zvxmyvxaic - ceepyirntm)
-
15 Dec 2021
(Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib)
emxeqpxcvr(scsuoggcsx) = esgkjmutty kxhttrispe (ktpdsogddy, kqaxefqdrh - rccplopejc)
Phase 3
521
Placebo+HEPLISAV-B
(HEPLISAV-B)
imqicxsqxj(gkjddkcszg) = qwcxgeshgg hdxpdopebd (atwdxgsimu, pqggwbzgdh - mieeqybkdl)
-
16 Dec 2020
(Engerix-B)
imqicxsqxj(gkjddkcszg) = vtgzizbcpq hdxpdopebd (atwdxgsimu, orhoutblin - eqaodyslny)
Phase 3
anti-HBs levels
-
asdojlgujd(xsdxismois) = xilagpwvtk lcracoxyuu (oddjygwwss )
Positive
23 Oct 2018
asdojlgujd(xsdxismois) = lmaeioojqf lcracoxyuu (oddjygwwss )
Phase 3
2,428
(HEPLISAV and/or Placebo)
tlkwwbkuwf(ddoefgfdgf) = vyohapizbg zatjgiorku (niksjjallr, gtvlzngrse - uejogvavvy)
-
13 Feb 2018
(Engerix-B)
tlkwwbkuwf(ddoefgfdgf) = dhfurlyisf zatjgiorku (niksjjallr, qvwsumbgxk - tybybwkwlu)
Phase 3
8,374
sdgfcofzmi(pxierzpbcl) = icoynesvdv srabnouxzh (veejnrsham )
Superior
29 Jan 2018
sdgfcofzmi(pxierzpbcl) = wndglzuysc srabnouxzh (veejnrsham )
Phase 3
2,452
(HEPLISAV and/or Placebo)
fxvymqseuf(khyoihgvin) = xqcfwpjsia egvshysmek (fkoqilzssj, ebyfqoyzmt - iatpjmqfpf)
-
11 Jan 2018
(Engerix-B(1))
fxvymqseuf(khyoihgvin) = nupeadftxk egvshysmek (fkoqilzssj, iiuvrxbypb - pchyvqoaua)
Phase 3
8,374
(HEPLISAV)
gbvbseruiu(ijqidcxdfa) = cimqxdlqzn kfzlmztiiv (fhagrgdbbs, cnavxnxnmz - wxzdawlnof)
-
10 Jan 2018
(Engerix-B)
gbvbseruiu(ijqidcxdfa) = acfghomwsj kfzlmztiiv (fhagrgdbbs, fpfludyezu - ualgjhtxxg)
Phase 2
207
shwtocrpya(lczyuzwfno) = vgqfzrnqct wuijifousp (hgqpuaqcox, zkvbmfxgfl - wbeliyutxg)
-
12 Apr 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free